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Botulinum toxin (BTX) blocks the release of
acetylcholine at theneuromuscularjunctionlead-
ing to a state of muscle paralysis that may last for
m o n t h s 1. It isconsideredas themostpotent biolo-
gicalneurotoxin,causing highmorbidityand death.
This fact led to misconception of the toxin in the
past2. However, over the past decade a complete
renewal of its image took place and nowadays
botulinum toxin is widely know as a therapeutic
agent with multiple indications3, specially after
being widelymarketedtothepublicasan antiwrin-
kletoolforfacial cosmetics. Nevertheless,ithasrev-
olutionized thetreatmentof manychronicneuro-
logicaldisorderswith markedimprovementin the
quality oflife anddisability dueto spasticity, hemi-
facialspasm,spasmodic dysphonia,hyperhidrosis,
as well as many dystonic conditions. In Brazil, BTX
was licensed for the treatment of various move-
ment disorders in 1992, and has been successfully
used in the management of blepharospasm (BP).
Beforethe adventofthis treatment,BP was consi-
dereda disabling condition with poor responseto
oral medications. Because it is a chronic disease, it
is important to ensure that the treatment strate-
gies are both safeandeffective after longperiods
ofmaintenance,andthatthepatientsreportsatis-
faction with the lengthy treatment.
Since there are no previous reports regarding
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ABSTRACT - To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of ble-
pharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders
Clinic of the Department of Neurology, Hospital das Clínicas, University of São Paulo School of Medicine
from 1993 to 2003. A total of 379 treatments with BTX were administered to 30 patients with ble-
pharospasm. Sixty six per cent of the subjects had used oral medication for dystonia and only 15% of them
reported satisfactory response to this treatment. Ninety three per cent of the patients showed significant
improvement after the first BTX injection. There was no decrement in response when compared the first
and the last injection recorded. Adverse effects, mostly minor, developed at least once in 53% of patients.
Six patients (20%) discontinued the treatment but there was no case of secondary resistance. 
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Toxina botulínica tipo A no tratamento do blefaroespasmo: experiência de 10 anos de utilização
RESUMO - Para avaliar os efeitos a longo prazo da toxina botulínica tipo A (BTX) no tratamento do ble-
faroespasmo foi realizado estudo retrospectivo no Ambulatório de Distúrbios do Movimento da Clínica
Neurológica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo de 1993 a
2003. Um total de 379 aplicações de BTX foram administradas a 30 pacientes com blefaroespasmo.
Previamente ao tratamento com toxina botulínica 63% dos pacientes utilizaram medicação oral para ble-
faroespasmo, mas apenas 15% referiu resposta satisfatória a este tratamento. Noventa e três por cento
dos pacientes tiveram resposta significativa à primeiraaplicação de BTX. Não houve decremento narespos-
ta quando comparadaa primeiraà últimaaplicaçãoregistradados pacientes.Efeitos adversos, em sua maio-
ria leves, ocorreram pelo menos uma vez durante o tratamento em 53% dos pacientes. Seis pacientes inter-
romperam o tratamento, mas não houve nenhum caso de resistência secundária.
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the long-term effects of BTX in the treatment of
blepharoespasm in our country, the aim of this ar-
ticle is to describe our findingsafter10-year expe-
rience.
METHOD
A retrospectiveanalysis wasconducted from data of
30 patients, who received botulinum neurotoxin type
A (Botox-Allergan) at the Movement Disorders Clinic of
the Department of Neurology, Hospital das Clínicas,
University of São Paulo School of Medicine (HC-USPSM)
over the past 10 years (1993 to 2003), to describe the
long-term efficacy and side effects of the treatment of
blepharospasm withBTX.Thepastmedicalhistoryofthe
patients regarding comorbidities and previoususe of oral
medication or surgical procedures were reported.
The schemeof injectionwasperformedaccordingto
a 10 symmetrical points modified from an original
scheme proposed by Consky4 (Fig 1). Sites of injection
were sometimes changed depending on the effects of
the toxin achieved after each application, either to en-
hance its efficacy or to decrease collateral effects. The
dose at the first application was usually 5 units per
point. In the following injections the dose was calculat-
ed based on the therapeutic response and tolerance.
The efficacy of the application wasevaluated bythe
Fig 2. Response to BTX applications. The data is displayed in bars showing the results in diff e r -
ent moments of the follow-up. Bars: A) Current response of the patients who achieved more
than10yearsoffollow-up. B)Lastregisteredapplicationresponseofallpatients. C)Currentresponse
ofallthepatientsstillonfollow-up. D) Firstapplicationresponseofallpatients. Statisticalanaly -
sis was performed comparing bars B, C and D to observe changes in response over time. There
was no significant difference between the response to the first and the last application regis -
teredfor each patient (bars D and B;p=0.7632according toa pairedStudent t test) orbetween
theresponsetothefirst applicationfor all patientsandthecurrentaverageresponseinpatients
who are still on follow-up (bars D and C; p=0.2365 according to a non-paired Student t test).
Fig 1. Injection points scheme for the treatment of
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patient based on a scale of subjective degree of func-
tional impairment (Columbia University Rating Scale)5.
Duration of the effect was also recorded and it was re-
ported by the patient as the time of maximum effect,
not including residual effects once its duration was
much longer, and many times lasting until the next ap-
plication. The interval between injections was establis-
hedaccordingtothedurationof effectobservedonpre-
viousinjections. Both the dosageand interval between
each application respected the general recommendations
for minimizingtherisk ofBTXantibodyformationinthe
treatment of neurological conditions6-8. General rules
for each procedure were: usage of minimum dose that
achieved best efficacy; avoidance of booster injections;
longest intervaltolerated and not shorterthan 3 months.
Prevalence of collateral effect wasreported by each pa-
tient in an all-or-none variable that would point to its
occurrence at least once during the treatment. 
RESULTS
A total of 379 treatments with multiple site in-
jections of BTX were administered to 30 patients
with BP in a 10-year period. The mean age of the
patients at the onset of the symptoms was 53.1
years (SD 9.87) and the mean age at the begging
of the treatment was 58 years; 80% of them were
female. Twenty two per cent of the patients met
criteria for Meige  syndrome (dystonic hyperactiv-
ity affecting not only the periocular muscles but
also muscles of the lower part of the face, such as
perioral, jaw and platismal muscles9), and 23% of
them had dystonia affecting other cranial or cer-
vicalregions,mainlycervicaldystonia (66%of the-
se patients). Previously to the BTX treatment 63%
of the patients had used oral medication for dys-
tonia(73%used biperiden,63%usedsomebenzo-
diazepine, 21% used baclofen; other drugs were
usedby a minorityofpatients).Only15%of these
patients reported good response with oral drugs. 
Ninety three per cent of the patients showed
significant improvement with the first BTX injec-
tion.Theaverageimprovementatthe firstapplica-
tion for those who responded was 69%. The aver-
age response to the injections for those who took
oral medicationspreviously to BTXtreatmentwas
74% and for those who did not use medications
62%; however, this difference was analyzed using
the Student t test and revealed to be not signifi-
cant (p=0.5272). The mean time of follow-up was
4.95 years, average of 12.63 applications per pa-
tient, and 60.93  units per application (SD=19.38).
The mean duration of improvement was 2.64
months. The average benefit reported at the last
application of all patients still on follow-up was
71.96%. Five patientsachieved 10 years of follow-
up,in thosethe mean response forthelastapplica-
tion was morethan10%higherthantheresponse
to the first application, but this difference was
not analyzed dueto thesmall numberof patients.
Ingeneral,there was nodecrement inresponsefor
thepatientsduringthefollow-upperiodascanbe
seen in Fig 2. 
Adverse effects, mostly minor, developed at
leastonceduringthetreatmentin53% ofpatients,
the most frequent was ptosis (81%) followed by
diplopia (12.5%). Six patients (20%) discontinued
treatmentfordiverse reasons.Of these,3present-
ed primary resistance.Two of themhadeye-open-
ing apraxia confirmed by eletroneuromyography.
One patient had only 1applicationwith no result,
and abandoned treatment. There was no case of
secondary resistance. One patient who did not
respondedadequately to BTX injections in the be-
ginningof her treatmentwasreferred toa neurec-
tomy and after this procedure presented satisfac-
toryresponseto BTX applicationswith an average
response rate of 60%.
DISCUSSION
Results evidenced that BTX injections offered
very good response rate with sustained eff e c t s
whiletheuseoforalmedicationwashighlyunsatis-
factory and did not interfere with the response to
the BTX treatment. In our opinion, a trial of oral
medication(alsosuggestedinliterature1 0)isrecom-
mendedsince in public servicesthe waiting list for
the BTX treatment is usually very long. 
In the literature some authors published simi-
lar results of long-term treatments for different
neurological movementdisorders1 1 , 1 2, hyperhydro-
s i s 1 3,aswe lla sothe rdise ase 1 4. About blep h a r o s p a s m ,
thereweresomecases includedin largetreatment
series for diverse neurological disorders and their
results resembled the ones observed in the pres-
ent study15. Concerns about long-term use of BTX
inthemusclecanberefutedsinceBorodic1 6 s h o w e d
noirreversiblemuscleatrophyin histologicalanaly-
sis of orbicularis oculi muscles of 11 patients who
had received botulinum toxin over 3.5 years.
Theapparent highrateofadverseeffects(53%)
can beexplainedin thisanalysis sincecollateralef-
fects were scored if they manifested at least once.
Thiscontrasts other data fromthe literature1 7 w h i c h
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collateral effect among the total number of injec-
tionsinashortperiod.Thistendsto reducetheper-
centageof reportedadverse effectssince they can
be avoided with changes in the procedure then
decreasing the rate of collateral effects in future
injections. Nevertheless, collateral effects were
well tolerated in our series and were not related
to abandonment of treatment. Ptosis is related to
the action of BTX on levator palpebrae muscle,
while diplopia is more uncommon and is usually
related to the effect of BTX in lateral rectus mus-
cle18, either for excessive diffusion of the toxin or
misplacement of theapplicationpointsinthesupe-
rior palpebrae. Bothcanbeavoidedbycorrection
of the injection site, decrease in the dosage or di-
lution. Ptosis can be prevented avoiding the cen-
tral portion of the eyelid and diplopia by placing
theneedlemorelaterallytotheinjectionsite. E y e -
opening apraxia, although fairly uncommon, has
beenpreviouslyrelatedto BTXresistance1 9,a ndi n
ourseries,thepatientsdropoutthetreatment.Al-
though secondary resistance to blepharospasm
treatment with botulinum toxin has been already
reported in the literature20, none of our patients
had this evolution.
Overall, the resultsshowedthatBTXwasa safe
and effective treatment for blepharospasm and
mostofthesideeffectswerewell tolerated.Levels
ofresponse in thepresentstudy were comparable
to thoseachieved in generalliterature.In thosese-
ries,mostofthepatientsreferredsubjectivedegree
of improvementbetween70%and90%2 0. Discon-
tinuationfordiverse reasonswas also low after10
yearsof follow-up.Inourseries,efficacywasmain-
tained after long periods of treatment with high
degree of patient satisfaction. 
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